Insulin Degludec · Tresiba, NN-1250

What is Insulin Degludec?

Insulin Degludec is a long-acting human insulin analog that binds the insulin receptor to regulate glucose metabolism. It stimulates peripheral glucose uptake by skeletal muscle and fat, inhibits hepatic glucose production, and suppresses lipolysis and proteolysis while enhancing protein synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Tresiba, NN-1250, Degludec IV, Degludec SC

Drug type

Recombinant protein

Targets

insulin receptor (INSR)

Mechanism

Agonist of insulin receptor (INSR)

Pathways

glucose metabolism, peripheral glucose uptake, hepatic glucose production inhibition, lipolysis inhibition, proteolysis inhibition

Therapy area

Endocrine

Developer

Novo

In trials of

LLY

FDA status

Approved as Tresiba (September 25, 2015), BLA203314 · FDA label

UNII

54Q18076QB

✅ FDA-approved uses

• Diabetes mellitus
• Diabetes mellitus

From the indications section of the FDA label (version of Feb 22, 2024). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Other drugs acting on INSR

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Insulin Degludec (2024-06-03), indications
• FDA label Tresiba (2024-02-22), indications

Updated Oct 3, 2026.